SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending after NVIDIA announced a $2 billion investment to expand AI factory capacity and strengthen their strategic partnership. This move is widely seen by the community as a significant validation of CoreWeave's position in the AI infrastructure buildout and a catalyst for massive GPU-centric data capacity expansion. However, some discussions revolve around the investment's specifics and its implications for CoreWeave's financial structure amid broader conversations about the AI compute sector.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is a top trend after securing significant funding from the U.S. government, aiming to bolster a domestic rare earth supply chain crucial for national security. The community is buzzing with optimism, anticipating a substantial surge and a potential short squeeze, though some caution about valuation and potential market pullbacks. This development is viewed as a pivotal move to reduce reliance on foreign sources for critical minerals.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. is experiencing a significant surge, driven by news of a strategic AI licensing deal and substantial preferred equity injection with Valio Technologies in Africa. The market is intensely focused on its extremely low float and high short interest, leading to widespread speculation of a massive short squeeze. This has ignited a lively debate within the community, with many predicting substantial upside while others caution about the stock's extreme volatility.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending following the release of positive three-year functional results from its EMBARK Phase 3 study for Elevidys, its gene therapy for Duchenne muscular dystrophy, demonstrating significant and durable slowing of disease progression. This data has ignited strong community debate, with many investors anticipating a substantial short squeeze and a re-rating of the "undervalued" stock, while others remain cautious given historical market reactions and perceived manipulation. The discussions underscore the importance of long-term efficacy in rare disease treatments and Sarepta's ongoing efforts to solidify its market position despite broader biotech skepticism.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending following its significant acquisition of SkyWater Technology, a strategic move aiming to create a vertically integrated quantum computing powerhouse with in-house chip manufacturing. This development, coupled with major quantum networking projects for the U.S. Air Force, has sparked intense community debate, with many viewing it as a pivotal step toward becoming the 'NVIDIA of Quantum Computing' while others express concerns about potential dilution and valuation.

Skywater Technology, Inc. is a holding company. It engages in the provision of semiconductor development, manufacturing services, and packaging services. The company was founded on October 3, 2016 and is headquartered in Bloomington, MN.

SkyWater Technology Inc

SkyWater Technology is currently trending due to the announced acquisition by IonQ for approximately $1.8 billion, with shares valued at $35 in a cash-and-stock deal. While the offer includes a notable premium, community sentiment is mixed, with many shareholders expressing strong disappointment and viewing the valuation as too low, even considering voting against the deal. This strategic move aims to forge the first vertically integrated quantum computing platform, blending IonQ's quantum technology with SkyWater's domestic semiconductor manufacturing capabilities.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending as investors react to the appointment of an OpenAI expert to its board of directors, signaling a strategic push into advanced AI and quantum-class computing. Community chatter highlights its low float and inclusion on short-squeeze lists, fueling speculative interest and comparisons to recent market runners in anticipation of a significant move.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is drawing significant attention as a multichain meme coin, actively discussed for its presence across Solana, BNB, Cronos, and Base chains via Layerzero technology. The community is buzzing about its deflationary burn mechanism and organic, decentralized nature, touting it as a unique contender in the crypto space.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony (UAMY) is trending as a critical domestic supplier of antimony, essential for national security, driving investor speculation around significant government investment and contracts. The community is highly bullish, emphasizing its integrated supply chain and existing $245 million government contract. Recent share acquisitions by the State of Alaska further fuel excitement in the burgeoning critical minerals sector, with many anticipating substantial price appreciation and potential short squeezes.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

Cel-Sci Corp

CEL-SCI is a top trending topic driven by discussions surrounding recent insider share purchases by its CEO, igniting hope among some for an imminent Breakthrough Medicine Designation from the Saudi FDA for Multikine. This optimism is vigorously debated, however, with skeptics pointing to a history of shareholder dilution and past trial outcomes, intensifying the conversation around the extended regulatory timeline and future funding for its upcoming US confirmatory study.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan

SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan SOPHiA GENETICS Provides Preliminary Fourth...

SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totaling 32,434 shares, a drop of...

SOPHiA GENETICS (NASDAQ:SOPH) Trading 2.8% Higher - What's Next?

SOPHiA GENETICS (NASDAQ:SOPH) Shares Up 2.8% - Here's What Happened...

AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave

AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave PR Newswire VANCOUVER, BC, Dec. 12, 2025 Issued...

321,527 Shares in SOPHiA GENETICS SA $SOPH Purchased by Archon Capital Management LLC

Archon Capital Management LLC bought a new stake in shares of SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) during the second quarter, according to the company in its most recent Form 13F filing...

Tempus AI's Data Business Is Expanding and Adding to Revenues: Here's How

TEM's surging Insights revenues, new contracts and expanded AI capabilities highlight its shift toward scalable data-driven growth.

Rathbones Group PLC Takes Position in SOPHiA GENETICS SA $SOPH

Rathbones Group PLC acquired a new stake in SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and...

SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine

SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to...

Complete Genomics and SOPHiA GENETICS Announce Integration of MSK-IMPACT and MSK-ACCESS Assays on DNBSEQ-T1+ Platform at AMP 2025

Complete Genomics and SOPHiA GENETICS Announce Integration of MSK-IMPACT and MSK-ACCESS Assays on DNBSEQ-T1+ Platform at AMP 2025 Complete Genomics and SOPHiA GENETICS Announce Integration of...

BTIG Research Boosts SOPHiA GENETICS (NASDAQ:SOPH) Price Target to $7.00

BTIG Research raised their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Monday...

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

SOPHiA Genetics SA

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

SOPH
SOPHiA Genetics SA

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SOPH News

SOPHSOPHiA Genetics SA